Twist Bioscience Launches MRD Express with Rapid Turnaround Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at scale with a rapid turnaround time starting within one day. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research, biomarker discovery and assay development. Molecular residual disease (MRD) is the presence.

Business Wire • 11 hours ago

Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review

The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.

Seeking Alpha • 8 hours ago

Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR binding characterization. Twist Express Screening Antibodies accelerate the path from sequence to purified antibody and binding characterization across br.

Business Wire • Oct 28, 2026

Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors

After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings beat. During the quarter, several key approvals and coverage expansions supported product growth for GH.

Seeking Alpha • Oct 28, 2026

Artisan Mid Cap Fund Q3 2026 Portfolio Update

The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We ended our investment campaign in Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals during the quarter.

Seeking Alpha • Oct 27, 2026

Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth quarter and full year ended September 30, 2026, before the opening of the market on November 12, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update.

Business Wire • Oct 26, 2026

Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.

Seeking Alpha • Oct 23, 2026

Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update

During Q3 2026, the Polen 5Perspectives Small-Mid Growth Composite Portfolio returned -12.5% (net of fees) compared to the -10.4% return of the Russell 2500 Growth Index. The top contributors to the Portfolio's relative performance in the quarter were Twist Bioscience, Twilio, and Embraer. The most significant detractors from the Portfolio's relative performance in the quarter were nLight, Terawulf, and BWX Technologies.

Seeking Alpha • Oct 15, 2026

How to Invest in AI Drug Discovery

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

ETF Trends • Oct 14, 2026

These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?

Moderna's stock has skyrocketed on exciting results from its personalized cancer vaccine. Twist Bioscience's synthetic DNA is enjoying strong demand.

The Motley Fool • Oct 12, 2026